title: Strategies for the in vivo inhibition of endogenous atriopeptin.
abstract: Pharmacological strategies have been employed to manipulate the response to atriopeptin (AP-28; ANF 99-126) in rats. These approaches include: heparin infusion which blocks the natriuresis-diuresis produced by exogenous AP infusion or by acute volume expansion; and autoimmune rats with endogenous antibody that blocks the natriuresis-diuresis produced by administration of exogenous AP or by acute volume expansion in anesthetized rats. Administration of the pressor analog 1-deamino-arg8-vasopressin (dAVP) to rats produces an elevation in systemic and right atrial blood pressure and markedly increases atriopeptin blood levels. The dAVP also produces a delayed natriuresis-diuresis which is effectively blunted in the autoimmune or heparin treated rats. The above approaches provide tools, in the absence of a specific receptor antagonist, with which to validate the intrinsic involvement of AP in physiological, pharmacological, or pathophysiological events.
authors.affiliation: Department of Pharmacology, Washington University School of Medicine, St. Louis, MO 63110.
authors.forename: M
authors.initials: M
authors.lastname: Sakata
authors.forename: P
authors.initials: P
authors.lastname: Needleman
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000037:antagonists & inhibitors*; D001327:Autoimmune Diseases / Q000378:metabolism; D001810:Blood Volume / Q000187:drug effects; D004231:Diuresis / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D009318:Natriuresis / Q000187:drug effects; D051381:Rats; D014667:Vasopressins / Q000494:pharmacology
chemical_list: D014667:Vasopressins; D009320:Atrial Natriuretic Factor; D006493:Heparin